What's Happening
Tilray and other cannabis stocks surged after reports that the Trump administration is preparing to reclassify cannabis, potentially moving it from Schedule I to a lower controlled-substance category. The move would unlock medical research pathways and banking services for growers currently locked out of traditional finance.
Market Impact
Cannabis equities rallied on the prospect of regulatory normalization and access to banking infrastructure—a structural unlock for the sector. Tilray, Canopy Growth, and smaller cultivators stand to benefit most from reduced compliance costs and expanded lending availability.
Broader Implications
Federal reclassification would represent a major shift in drug policy and could accelerate state-level legalization momentum. However, the move remains pending; any delay or reversal would trigger sharp sector pullbacks.
